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Abstract
Heat shock protein 90 (Hsp90) inhibition by modulation of the N-or C-terminal binding site has 
become an attractive strategy for the development of anti-cancer chemotherapeutics. The first 
Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC50 value of ~700 μM. 
Therefore, investigation of the novobiocin scaffold has led to analogs with improved 
antiproliferative activity (nanomolar concentrations) against several cancer cell lines. During these 
studies, novobiocin analogs that do not inhibit Hsp90 were identified; however, these analogs 
demonstrated potent anti-proliferative activity. Compound 2, a novobiocin analog, was identified 
as a MAPK pathway signaling disruptor that lacked Hsp90 inhibitory activity. In addition, 
structural modifications of compound 2 were identified that segregated Hsp90 inhibition from 
MAPK signaling disruption. These studies indicate that compound 2 represents a novel scaffold 
for disruption of MAPK pathway signaling and may serve as a useful structure for the generation 
of new anti-cancer agents.
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INTRODUCTION
Heat shock protein 90 (Hsp90) is a molecular chaperone that facilitates the conformational 
maturation of other cellular proteins, termed clients, via the Hsp90 chaperone cycle. Hsp90 
functions as a homodimer and each monomer comprises an N-terminal domain (the site of 
ATP-binding and hydrolysis), a middle domain, and a C-terminal dimerization domain. 
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Inhibitors that target the N-and C-termini of Hsp90 can halt client maturation and lead to 
ubiquitinylation and degradation of the substrate via the proteasome1–5. N-terminal 
inhibitors perturb ATPase activity at the N-terminus and include derivatives of the natural 
product geldanamycin. However, N-terminal inhibition also leads to induction of the pro-
survival heat shock response (HSR) via Heat Shock Factor-1. This led to the development of 
C-terminal inhibitors, in which the HSR is avoided and client degradation is maintained. 
There are several therapeutic opportunities for small molecules that target the Hsp90 N-or C-
terminus, including the development of anticancer chemotherapeutics6–20.
Novobiocin is a natural product that inhibits the Hsp90 C-terminus and was found to exhibit 
an IC50 value of ~700 μM against the SKBr3 breast cancer cell line (Figure 1)21. Extensive 
structure-activity relationship (SAR) studies on novobiocin have greatly improved anti-
proliferative activity against many different cancer cell lines and identified structural 
elements necessary for Hsp90 inhibition; however, exploration of the amide linker has yet to 
be fully investigated22–40.
During SAR studies of the urea linker that was probed as a surrogate for the amide, 
analogues were identified that exhibited potent anti-proliferative activity against several 
cancer cell lines. However, some of the compounds did not inhibit Hsp90. Investigation of 
these analogues led to identification of 2, a novobiocin analogue that exhibited potent anti-
proliferative activity against the MCF7 breast and A549 lung cancer cell lines without 
Hsp90 inhibitory activity. Instead, compound 2 was shown to disrupt mitogen-activated 
protein kinase (MAPK) signaling and in a time-dependent manner inhibited the 
phosphorylation of MEK and ERK. Since oncogenic mutations frequently occur within the 
MAPK pathway, much research has been devoted to the development of inhibitors of this 
pathway, including EGFR, Raf, MEK and ERK41–43. Preliminary SAR studies of 2 
examined the necessity of each methoxy substitution on the biaryl side chain and identified 
moieties that transition novobiocin analogues from Hsp90 inhibitory activity, such as 
compound 1, to MAPK pathway inhibitors (Figure 1).
RESULT AND DISCUSSION
As shown in Scheme 1, compound 1 was prepared in one step by coupling the previously 
reported aniline 639 with the commercially available phenylisocyanate, 7a. Compound 2 was 
synthesized from biaryl acid 839, using diphenylphosphorylazide to give the corresponding 
azide, which underwent Curtius rearrangement to afford phenylisocyanate, 7b. Subsequent 
coupling of 7b with intermediate 6, provided compound 2 in good yield.
Many client proteins that depend upon Hsp90 are up-regulated and oftentimes represent 
signaling pathways that are hijacked during malignant transformation16,18,44,45. Compounds 
that inhibit Hsp90, or the Hsp90 chaperone cycle, lead to client protein degradation via the 
ubiquitin proteasome pathway and deprive cancer the use of clients that drive progression 
and growth1,4,5,46. Therefore, decreased client protein levels are observed at the IC50 values 
obtained in cell proliferation assays for Hsp90 inhibitors. To determine whether a compound 
inhibits Hsp90, IC50 values are generated against cancer cell lines that depend upon 
functional Hsp90. The estrogen receptor-expressing MCF7 breast cancer cell line and the 
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KRAS-driven A549 lung cancer cell line both depend upon Hsp90 for client protein 
maturation. Therefore, compounds that exhibit potent anti-proliferative activity against these 
cell lines may inhibit Hsp90. Table 1 shows the IC50 values for compounds 1 and 2 
generated against these cancer cell lines, as well as the normalized cell line, MRC-5. 1 and 2 
were shown to exhibit potent inhibition of cancer cell growth compared to the MRC-5 line, 
indicating the cellular target(s) for these compounds facilitate cancer growth.
Client protein levels in MCF7 and A549 cells were determined via Western blot analysis 
after incubation with low and high concentrations of 1 and 2 (L = half the IC50 value; H = 
five-times the IC50 value, respectively; Figure 2). If client levels are unaffected upon 
incubation with low concentrations of the compound and decreased at high concentrations, 
the compound is likely to inhibit Hsp90 function.
Incubation with high concentrations of 1 led to decreased levels of the Hsp90-dependent 
clients EGFR, Her2 and C-Raf in both MCF7 and A549 cell lysates, when compared to 
vehicle control (Figure 2). Hsp90 levels at low and high concentrations of 1 were 
comparable to vehicle and indicative of Hsp90 C-terminal inhibition37. Furthermore, 
incubation with the N-terminal inhibitor, geldanamycin (GDA), led to decreased client levels 
at concentrations that increased cellular levels of Hsp90 (Supplementary Figure 1)47,48. 
These data suggest the mechanism of action manifested by compound 1 is inhibition of the 
Hsp90 C-terminus, as opposed to N-terminal inhibition.
In contrast, client protein levels were unchanged after incubation with low and high 
concentrations of 2 against both MCF7 and A549 cells. Since no Hsp90-dependent client 
protein degradation was observed with compound 2, the data suggests this compound 
inhibits cancer cell growth unrelated to Hsp90 inhibition. The luciferase refolding activity 
was measured for the compound 2 to confirm whether this compound has Hsp90 inhibitory 
activity. The data demonstrates that compound 2 does not inhibit the re-maturation of firefly 
luciferase, similar to DMSO treated cells (Figure 2). In contrast, the novobiocin analog, 
KU-257, which inhibits Hsp9039, was shown to inhibit luciferase re-maturation (Figure 2). 
These results further confirm that compound 2 inhibits cancer cell growth unrelated to 
Hsp90 inhibition. Given the potent antiproliferative activity manifested by 2 against both 
cancer cell lines as well as the selective inhibition of cancer cell growth, the mechanism by 
which 2 manifests this anti-cancer activity was pursued.
Since 2 exhibited potent anti-proliferative activity against the non-small cell lung cancer cell 
line A549 and generated an IC50 value of 0.15 ± 0.02 μM, subsequent studies were initiated 
with this cell line. The A549 cell line expresses wild type B-Raf, C-Raf and mutant KRAS. 
Proliferation of the A549 cell line is driven by over-activation/expression of proteins 
involved in the Ras-Raf-MEK-ERK (MAPK) pathway and consequently, this cell line is 
commonly utilized to identify small molecule kinase inhibitors that target Raf, MEK and/or 
ERK49. Interestingly, many inhibitors that target kinases involved in the MAPK pathway 
display structural similarities to compound 2 (Figure 3).
Given the potent anti-proliferative activity exhibited by 2 against the MAPK-driven A549 
cancer cell line, and the structural similarities between 2 and known disruptors of this 
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pathway, it was hypothesized that 2 may inhibit the A549 cancer growth through disruption 
of MAPK signaling. Therefore, to determine whether 2 inhibits kinases within the MAPK 
pathway, Western blots for phosphorylated proteins involved in the MAPK pathway were 
performed using A549 lysates treated with 2 at 750 nM (five-times the IC50 value) for two 
to 12 hours (Figure 4A). Treatment with 2 led to a time-dependent decrease in 
phosphorylated MEK and ERK suggesting this compound inhibits kinase activity; however, 
decreased levels of phospho-MEK (p-MEK) and phospho-ERK (p-ERK) were observed at 
different incubation times. Decreased p-MEK levels occurred after four hours of incubation 
with 2 and were undetectable after 12 hour incubation. In contrast, decreased p-ERK levels 
were only observed after six hours of incubation and continued to decrease during the 12 
hour incubation. These data indicate that 2 disrupts kinase activity upstream of MEK and 
ERK; 2 prevented phosphorylation of MEK, which subsequently prevented phosphorylation 
of ERK. The levels of other proteins crucial for MAPK signaling, such as EGFR and C-Raf, 
remained constant at each time point and were comparable to vehicle control. C-Raf is an 
Hsp90 client and undergoes proteolytic degradation upon 12 hours of incubation with Hsp90 
inhibitors. After 12 hours of incubation with 2, C-Raf levels were similar to vehicle and 
remained constant at each time point, which demonstrates that compound 2 inhibits cancer 
cell growth by a mechanism unrelated to Hsp90 inhibition. Total MEK and ERK levels also 
remained constant at each time point and were comparable to vehicle, indicating that 
decreased p-MEK and p-ERK levels were not the result of decreased MEK and ERK levels. 
To determine whether 2 inhibits general kinase activity, Western blots were generated for 
phosphorylated Akt (p-Akt) and total Akt levels using A549 cell lysates after two to 12 
hours of incubation. Akt is phosphorylated by phosphoinositide 3-kinase (PI3K), and p-Akt 
formation is unrelated to the MAPK pathway50. Supplementary Figure 2 demonstrates that 
p-Akt and total Akt levels were unaffected at each time point, which suggests that 2 
preferentially inhibits phosphorylation of the MAPK pathway proteins.
Figure 4B shows a concentration-dependent decrease in p-MEK and p-ERK after 12 hours 
of incubation with 2. A low concentration of 2 (L; half the IC50 value, 70nM) had little 
effect on cellular levels of p-MEK and p-ERK; however, incubation with a high 
concentration of 2 (five-times the IC50 value, 750 nM) resulted in significantly lower levels 
of p-MEK and pERK, which were consistent with previous observations. Little effect was 
observed on the levels of other MAPK-associated proteins, as well as total MEK and ERK 
levels at either concentration.
It is well established that small molecule inhibition of the MAPK pathway activates multiple 
feed-back mechanisms that ultimately result in up-regulated MAPK pathway activity51–54. 
In vitro, this occurs at short incubation times and can be observed up to 24 hours after 
incubation with inhibitors of the MAPK pathway (via increased levels of p-MEK and p-ERK 
as well as increased transcription of MAPK proteins and proteins that support feed-back 
mechanisms). Western blot analysis of MAPK pathway proteins, p-MEK and p-ERK from 
A549 cell lysates treated with high concentrations of 2 (750 nM) for 12 and 24 hours were 
conducted (Figure 4B). After 24 hours of incubation, p-MEK and p-ERK levels were only 
slightly increased compared to 12 hours of incubation; however, these levels remained lower 
than vehicle control, which could result from the up-regulation of MAPK pathway activity 
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via a feed-back mechanism or the consequence of compound 2 instability, which may 
produce metabolites that no longer interact with the cellular target(s).
To determine whether re-establishment of detectable p-MEK and p-ERK levels after 24 
hours of incubation with 2 was the result of feed-back mechanism activation, Western blots 
for Her3 and wild-type B-Raf levels were performed. Her3 and wild type B-Raf are 
expressed at relatively low levels in cancer cells under normal conditions. However, 
inhibition of MAPK pathway activity via small molecule EGFR, Raf or MEK inhibitors 
induce Her3 and wild-type B-Raf overexpression to compensate for decreased p-MEK and 
p-ERK signaling. After 24 hours of incubation with 2, Her3 and wild-type B-Raf levels were 
comparable to vehicle and indicated no activation of a feed-back mechanism (Figure 5). 
Western blots for Her3 and wild-type B-Raf levels from A549 lysates treated with control 
compounds (sorafenib, vemurafenib and TAK-632) for 12 and 24 hours were also performed 
(Figure 5). Sorafenib is a kinase inhibitor and incubation with sorafenib at five-times the 
reported IC50 value (14 μM) resulted in decreased p-MEK and p-ERK levels and a time-
dependent increase in Her3 levels (Supplementary Figure 3; Figure 5)49. Vemurafenib and 
TAK-632 are Raf inhibitors. Vemurafenib is a mutant B-Raf inhibitor that is relatively 
inactive against the A549 cell line, which expresses only wild-type B-Raf. Incubation with a 
high concentration of vemurafenib (five-times the reported IC50 value against the A549 
cancer cell line, >50 μM) had little effect on Her3 and wild-type B-Raf levels, as well as 
MAPK pathway signaling after 12 and 24 hours (Figure 5; Supplementary Figure 3)55. 
TAK-632 is a kinase inhibitor that preferentially inhibits wild-type B-Raf and C-Raf, and 
ultimately leads to decreased p-MEK and p-ERK levels (Supplementary Figure 3). Her3 and 
wild-type B-Raf levels remained unaffected after 12 and 24 hours of incubation with 
TAK-632 at five-times the reported IC50 value (8.5 μM) which is comparable to 2 (Figure 
5)56. These data indicate that 2 prevents p-MEK and p-ERK formation via a mechanism 
similar to TAK-632, which targets wild-type B-Raf and C-Raf.
It has been previously reported that Raf inhibitor treatment leads to hetero-dimerization 
between wild type B-Raf and c-Raf causing re-establishment of MAPK pathway signaling 
and cancer proliferation57. Therefore, a co-immunoprecipitation assay was performed to 
investigate whether compound 2 activates the MAPK pathway by heterodimer formation. 
The results provided in Figure 6 demonstrate that 2 does not result in dimerization of wild 
type B-Raf and c-Raf.
In lieu of the biaryl side chain, the incorporation of a phenyl ring onto the urea linker (1) 
results in Hsp90 inhibition as observed via client protein degradation (see Figure 2), while 
replacement of the phenyl substituent with a bulky di-methoxy biaryl side chain leads to 
disruption of the MAPK pathway. Therefore, compounds 3, 4 and 5, which contain 
substitutions about the biaryl side chain were synthesized to identify substitutions that 
distinguish Hsp90 inhibitory activity from MAPK pathway inhibition (Scheme 2). 
Compound 3 contains a biaryl side chain with no methoxy groups, while 4 and 5 each 
contain a single methoxy substitution on the biaryl side chain. IC50 values for each 
compound were determined against the A549 cancer cell line as shown in Table 2. Each 
compound exhibited potent anti-proliferative activity within the nanomolar concentration 
range.
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Western blot analyses for Hsp90 clients were performed using A549 cell lysates dosed for 
12 and 24 hours with high concentrations of each compound (five-times the IC50 value) to 
identify Hsp90 inhibitors (Figure 7A). After 24 hours of incubation with 3, decreased levels 
of Hsp90-dependent client proteins were observed while constant levels of Hsp90 remained, 
suggesting that 3 is an Hsp90 C-terminal inhibitor. Single methoxy substitutions on the 
biaryl side chain (4 and 5) did not result in decreased client levels after 12 or 24 hours of 
incubation, indicating no Hsp90 inhibition. Western blot analyses for MAPK pathway 
proteins and p-MEK and p-ERK levels were performed using the A549 cell lysates dosed for 
12 and 24 hours with 4 and 5 and are shown in Figure 7B. 12 hours of incubation with 4 led 
to decreased p-MEK and pERK levels compared to vehicle; however in contrast to 2, p-
MEK and p-ERK levels were reestablished after 24 hours of incubation with 4 and 5. P-ERK 
levels were also decreased after 12 hours of incubation with 5; however, 24 hours of 
incubation resulted in p-ERK levels that were comparable to vehicle. After 12 and 24 hours 
of incubation with 5, p-MEK levels were unchanged.
These data indicate that both methoxy substitutions on the biaryl side chain are important for 
prolonged MAPK pathway disruption. While mono-methoxy substitutions inhibited p-MEK 
and/or p-ERK formation, neither substitution alone was able to sustain inhibitory activity to 
the extent of the dimethoxy-substituted side chain present in 2.
CONCLUSIONS
In conclusion, 2 was synthesized during SAR studies of novobiocin-based Hsp90 C-terminal 
inhibitors that contain urea surrogates of the amide linker. 1 was identified as an Hsp90 
inhibitor via Hsp90-dependent client degradation, however, 2 failed to exhibit Hsp90 
inhibitory activity. Upon further investigation, 2 was shown to disrupt the MAPK pathway 
signaling by preventing p-MEK formation after 4 hours of incubation, which ultimately 
disrupted p-ERK formation. Disruption of p-MEK and p-ERK formation was comparable to 
the control compound TAK-632, a Raf inhibitor that preferentially inhibits wild type B-Raf 
and C-Raf; however, 2 exerted this activity at one tenth the IC50 value of TAK-632 (IC50 
value of 0.15 ± 0.02 μM versus 1.7 μM against the A549 lunger cancer cell line). While 
individual methoxy substitutions on the biaryl side chain inhibit p-MEK and/or p-ERK 
formation, the dimethoxy-substituted biaryl sidechain is required for sustained inhibition. 
Therefore, 2 represents a novel, novobiocin-based scaffold for the development of MAPK 
pathway inhibitors and appears to manifest a similar mechanism of action to TAK-632 and 
target C-Raf and wild-type B-Raf.
EXPERIMENTAL SECTION
Chemistry
General Methods—1HNMR were recorded at 400 or 500 MHz (Bruker DRX-400 Bruker 
with a H/C/P/F QNP gradient probe) spectrometer and 13C NMR spectra were recorded at 
100 or 125 MHz (Bruker DRX 500 with broadband, inverse triple resonance, and high 
resolution magic angle spinning HR-MA probe spectrometer); chemical shifts are reported 
in δ (ppm) relative to the internal reference chloroform-d (CDQ3, 7.27 ppm) or dimethyl 
sulfoxide-d6 (DMSO-d6, 2.50 ppm). High resolution mass spectra (FAB) were recorded with 
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a LCT Premier (Waters Corp., Milford, MA) spectrometer. The purity of all compounds was 
determined to be >95% as determined by HPLC analysis. TLC was performed on 
glassbacked silica gel plates (Uniplate) with spots visualized by UV light. All solvents were 
reagent grade and when necessary, were purified and dried by standard methods. 
Concentration of solvents occurred via the use of a rotary evaporator operating at reduced 
pressure.
General procedure for the synthesis of urea derivatives: 1-(8-methyl-7-((1-
methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-3-phenylurea (1) Phenyl isocyanate (17 
mg, 0.14 mmol) was added to a solution of amine 639 (20 mg, 0.07 mmol) in 
dichloromethane (2 mL) and stirred at r.t. overnight. The resulting mixture was concentrated 
and purified via column chromatography (SiO2, 10:1 CH2Cl2: methanol) to afford 1 as a 
light brown amorphous solid (22 mg, 78 %): 1H NMR (400 MHz, CDQ3) δ 8.75 (s, 1H, 
NH), 8.52 (s, 1H, NH), 8.42 (s, 1H), 7.54 (d, J = 7.7 Hz, 2H), 7.23 – 7.12 (m, 3H), 6.93 (t, J 
= 7.3 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 4.39 (m, 1H), 2.70~2.62 (m, 1H), 2.40~2.33 (m, 
2H), 2.32 (s, 3H), 2.32 (s, 3H), 2.06 – 1.82 (m, 2H), 1.90~1.88 (m, 2H). 13C NMR (126 
MHz, DMSO) δ 158.31, 155.48, 152.28, 148.17, 139.27, 128.93, 125.25, 122.61, 122.21, 
120.39, 117.99, 113.45, 113.40, 110.96, 71.60, 51.58, 45.14, 29.77, 8.16. HRMS (ESI+) m/z 
[M+H+] calcd for C23H26N3O4 408.1923; found 408.1919.
1-(3′,6-dimethoxy-[1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-
oxo-2H-chromen-3-yl)urea (2) Compound 2 was obtained as a white amorphous solid (15 
mg, 82%): 1H NMR (500 MHz, CDCl3+CH3OH) δ 8.26 (s, 1H), 7.33 – 7.29 (m, 2H), 7.19 
– 7.14 (m, 2H), 6.97 – 6.95 (m, 2H), 6.82 (d, J = 8.8 Hz, 1H), 6.74 (d, J = 8.1 Hz, 2H), 4.39 
(m, 1H), 3.70 (s, 3H), 3.65 (s, 3H), 2.60 (m, 2H), 2.40 (m, 2H), 2.25 (s, 3H), 2.17 (s, 3H), 
1.91 (m, 2H), 1.81 (m, 2H). 13C NMR (126 MHz, CDQ3+CH3OH) δ 159.62, 159.02, 
155.78, 153.52, 152.56, 148.66, 139.45, 131.64, 130.85, 128.82, 124.95, 122.57, 122.49, 
121.91, 121.75, 120.06, 115.08, 114.68, 113.90, 112.45, 111.94, 110.44, 55.79, 55.04, 
51.66, 45.41, 29.78, 7.97. HRMS (ESI+) m/z [M+H+] calcd for C3iH34N3O6 544.2448; 
found 544.2443.
1-([1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-
yl)urea (3) Compound 3 was obtained as a brown amorphous solid (27 mg, 76%): 1H NMR 
(500 MHz, DMSO) δ 9.60 (s, 1H, NH), 8.73 (s, 1H, NH), 8.44 (s, 1H), 7.88 (s, 1H), 7.65 – 
7.61 (dd, J = 8.3, 1.1 Hz, 2H), 7.52 – 7.47 (m, 2H), 7.42 – 7.37 (m, 2H), 7.36 – 7.32 (m, 
1H), 7.31 – 7.27 (dt, J = 7.6, 1.3 Hz, 1H), 7.11 – 7.06 (d, J = 8.9 Hz, 1H). 4.54 (m, 1H), 2.59 
(m, 2H), 2.31 (m, 2H), 2.23 (s, 3H), 2.22 (s, 3H), 1.95 (m, 2H), 1.73 (m, 2H). 13C NMR 
(126 MHz, DMSO) 5 158.29, 155.55, 152.31, 148.14, 140.93, 140.19, 139.81, 129.48, 
128.93, 127.54, 126.61, 125.21,122.46, 120.62, 120.49, 117.04, 116.17, 113.35, 113.28, 
110.93, 72.06, 51.83, 45.66, 30.23, 8.09. HRMS (ESI+) m/z [M+H+] calcd for C29H30N3O4 
484.2236; found 484.2232.
1-(6-methoxy-[1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-
chromen-3-yl)urea (4) Compound 4 was obtained as a white amorphous solid (22 mg, 
71%): 1H NMR (500 MHz, CDCl3) δ 8.60 (s, 1H), 8.43 (s, broad, 2H, NH), 7.60 (dd, J = 
8.8, 2.6 Hz, 1H), 7.55 – 7.50 (m, 3H), 7.39 (t, J = 7.5 Hz, 2H), 7.35 – 7.31 (m, 1H), 7.25 (d, 
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J = 8.6 Hz, 1H), 6.93 (d, J = 8.9 Hz, 1H), 6.83 (d, J = 8.8 Hz, 1H), 4.42 (m, 1H), 3.79 (s, 
3H), 2.68 (m, 2H), 2.42 (m, 2H), 2.38 (s, 3H), 2.09 (s, 3H), 2.04 (m, 2H), 1.91 (m, 2H). 13C 
NMR (126 MHz, CDQ3+CH3OH) δ 159.65, 155.85, 153.56, 152.57, 148.66, 138.05, 
131.68, 131.04, 129.29, 127.81, 126.87, 124.91, 122.60, 122.43, 121.77, 119.91, 114.68, 
113.83, 111.90, 110.45, 71.37, 55.75, 51.76, 45.52, 29.90, 7.96. HRMS (ESI+) m/z [M+H+] 
calcd for C30H32N3O5 514.2342; found 514.2339.
1-(3′-methoxy-[1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-
oxo-2H-chromen-3-yl)urea (5) Compound 5 was obtained as a brown amorphous solid (15 
mg, 76%): 1H NMR (500 MHz, DMSO) δ 9.59 (s, 1H, NH), 8.73 (s, 1H, NH), 8.44 (s, 1H), 
7.84 (s, 1H), 7.52 – 7.49 (d, J = 8.6 Hz, 1H), 7.43 – 7.35 (m, 3H), 7.32 – 7.28 (dt, J = 7.0, 
1.8 Hz, 1H), 7.22 – 7.18 (m, 1H), 7.16 – 7.13 (t, J = 2.1 Hz, 1H), 7.11 – 7.07 (d, J = 8.9 Hz, 
1H), 6.99 – 6.94 (dd, J = 8.2, 2.5 Hz, 1H), 4.55 (m, 1H), 3.83 (s, 3H), 2.60 (m, 2H), 2.33 (m, 
2H), 2.24 (s, 3H), 2.23 (s, 3H), 1.96~1.92 (m, 2H), 1.73~1.72 (m, 2H). 13C NMR (126 MHz, 
DMSO) δ 159.66, 158.29, 155.54, 152.30, 148.15, 141.71, 140.80, 139.74, 130.00, 129.43, 
125.23, 122.46, 120.73, 120.50, 118.95, 117.19, 116.27, 113.36, 113.29, 112.95, 112.24, 
110.93, 71.99, 55.10, 51.80, 45.60, 30.17, 8.10. HRMS (ESI+) m/z [M+H+] calcd for 
C30H32N3O5 514.2342; found 514.2346.
Biology
Antibodies and Reagents: Antibodies targeting Akt 1/2/3 and actin were purchased from 
Santa Cruz Biotechnology. The antibody targeting Hsp90 was purchased from Thermo 
Scientific (PA3-013). The following antibodies were purchased from Cell Signaling: EGF 
Receptor, p44/42 MAPK, P-p44/42 MAPK, MEK1/2, P-MEK1/2, pAkt, BRaf, CRaf, Her3/
ErbB3 and Her2/ErbB2. Geldanamycin was purchased from Sigma Aldrich and sorafinib, 
vemurafinib and TAK-632 were purchased from Selleckchem.
Cell Culture: the media for each cell line was supplemented with streptomycin (500 μg/mL), 
penicillin (100 units/mL), and 10% FBS. MCF7 cells were maintained in Advanced 
DMEM/F12 (1:1; Gibco) supplemented with L-glutamine (2 mM). A549 cells were 
maintained in F12K (Cellgro). MRC-5 cells were maintained in DMEM (Cellgro). Cells 
were grown in a humidified atmosphere (37 °C, 5% CO2) and passaged when confluent.
Anti-proliferation: cells were grown to confluence, seeded (2000 cells/well, 100 μL total 
media) in clear, flat-bottom 96-well plates and allowed to attach overnight. Compound at 
varying concentrations in DMSO (1% DMSO final concentration) was added. Cells were 
returned to the incubator for an additional 72 h. After 72 h, cell growth was determined 
using an MTS/PMS cell proliferation kit (Promega) per the manufacturer’s instructions. 
Cells that incubated in 1% DMSO were used as 100% proliferation (i.e. DMSO = 100% 
growth) and the relative growth for each compound concentration was compared to 1% 
DMSO. IC50 values were calculated from two separate experiments performed in triplicate 
using GraphPad Prism 6.0.
Western Blot: cells were grown to confluence and seeded at 0.4 × 106 cells/well/2 mL. Cells 
were incubated for 24 hours and treated with compound in DMSO (0.25% DMSO final 
concentration), or vehicle (DMSO) for the indicated amount of time. Cells were harvested in 
Hall et al. Page 8













cold PBS and lysed using MPER (Thermo Scientific) supplemented with protease and 
phosphatase inhibitors (Roche) according to manufacturer’s directions. Lysates were 
clarified at 14,000g for 15 minutes at 4° C. Protein concentrations were determined using 
the Pierce BCA protein assay kit per the manufacturer’s instructions. Equal amounts of 
protein (15 μg) were electrophoresed under reducing conditions (10% acrylamide gels), 
transferred to PVDF, and immunoblotted with the corresponding antibody. Membranes were 
incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed 
with a chemiluminescent substrate, and visualized.
Co-immunoprecipitation: A549 cell lines were plated in 10 cm cell culture dishes or T25 
flasks and allowed to grow to ~80% confluency. A549 cell lines were received DMSO 
(0.1%) (Vehicle), or the indicated drugs dissolved in DMSO at indicated concentrations for 
24 h. After drug treatments A549 cell lines were harvested in lysis buffer containing 0.1% 
NP40, 50 mM Tris (pH 7.5), 150 mM NaCl, protease and phosphatase inhibitor cocktails 
(Roche). Lysates were clarified and protein concentration was determined using BCA assay. 
For co-immunoprecipitation, 500 μg of total protein was diluted to 500 μL total volume in 
lysis buffer and incubated with 10 μl of primary antibody overnight at 4 °C with rocking. 
Immune complexes were captured with 30 μL of DynaBeads Protein G (Invitrogen) for 3 h 
with rocking at 4 °C. Protein G Bead complexes were washed three times with lysis buffer 
and eluted with sample buffer. Samples were then boiled and subjected to SDS-PAGE and 
Western blot analysis.
Luciferase Refolding Assay: Compound at varying concentrations in DMSO (1% DMSO 
final concentration) was added to wells of a white, round-bottom 96-well plate containing 50 
μL of DMEM media. Luciferase-expressing PC3-MM2 cells were grown to confluence, 
collected, and incubated for 8–12 min at 50 °C in pre-warmed DMEM media until 
bioluminescence of luciferase was reduced to 1% of the initial counts. Cells were added 
(60,000 cells/50 μL) to wells (final concentration of 60,000 cells/100 μL), and the plate was 
returned to the incubator for 1 h. After 1 h, 100 μL of luciferase substrate reagent (75 mM 
tricine at pH7.8, 24 mM MgSO4, 0.3 mM EDTA, 2 mM DTT, 0.313 D-luciferin, 0.64 mM 
coenzyme A, 0.66 mM ATP, 150 mM KCl, 10% Triton-X, 20% glycerol, and 3.5% DMSO) 
was added to wells, and the bioluminescence was immediately read (0.5 s integration time). 
Cells that were incubated in 1% DMSO were used as 100% bioluminescence (i.e., DMSO = 
100% refolding), and the relative refolding for each compound concentration was compared 
to that in 1% DMSO. The concentrations for each compound were in triplicate, and dose-
response curves were generated using GraphPad Prism 5.0.
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Refer to Web version on PubMed Central for supplementary material.
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Structures of novobiocin, compound 1 and 2.
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(A) Western blot for Hsp90 client proteins (EGFR, Her2 and Raf) and Hsp90 using MCF7 
and A549 cell lysates treated for 12 hours with vehicle (0.25% DMSO), a low concentration 
(L; half the IC50 value) or a high concentration (H; five-times the IC50 value) of compound 
1 or 2 (B) The luciferase refolding activity of Hsp90 in PC3-MM2 cells with vehicle 
(DMSO), compounds 1 and 2, and the positive control, KU-257. The concentrations used 
were 0–100 μM.
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Structures and the overlay of compound 2 (green) with sorafenib (gray; a kinase inhibitor 
that targets B-Raf and C-Raf), TAK-632 (magenta; a kinase inhibitor that targets C-Raf and 
wild-type B-Raf) and with vemurafenib (yellow; an inhibitor of mutant B-Raf).
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(A) Western blot for proteins of the MAPK pathway (EGFR, C-Raf, MEK, ERK) and 
phosphorylated MEK and ERK (p-MEK and p-ERK) from A549 cell lysates treated for two 
to 12 hours with five times the IC50 value of 2 or vehicle (0.25% DMSO) (B) Western blot 
for proteins of the MAPK pathway and phosphorylated MEK and ERK from A549 cell 
lysates treated for 12 or 24 hours with five-times the IC50 value of 2 or vehicle (0.25% 
DMSO).
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Western blot for proteins Her3 and wild-type B-Raf from A549 cell lysates treated for 12 or 
24 hours with five-times the IC50 value of 2, sorafenib, vemurafenib, TAK-632 or vehicle 
(0.25% DMSO).
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A. Co-immunoprecipitation of B-Raf from A549 cell lysates treated for 24 hours with five-
times the IC50 value of 2, sorafenib, or vehicle (0.25% DMSO). B-Raf immunoprecipitated 
c-Raf in sorafenib treated cells, but not 2 treated cells. B. Proposed mechanism of action for 
compound 2 and sorafenib. In wild type B-Raf cells, basal level of B-Raf C-Raf dimerization 
occurs. In sorafenib treated cells, the B-Raf C-Raf dimerization is prevalent causing 
activation of the MAPK pathway, resulting in growth. In contrast, compound 2 prevents 
hetero-dimerization of B-Raf and C-Raf, and consequently, the MAPK pathway is not 
activated.
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(A) Western blot for Hsp90 client proteins (EGFR, Her2 and C-Raf) and Hsp90 using A549 
cell lysates treated for 12 or 24 hours with a high concentration (five-times the IC50 value) 
of 3, 4, 5 or vehicle (0.25% DMSO). (B) Western blot for proteins of the MAPK pathway 
(EGFR, C-Raf, MEK, ERK) and phosphorylated MEK and ERK (p-MEK and p-ERK) from 
A549 cell lysates treated for 12 or 24 hours with five-times the IC50 value of 4, 5 or vehicle 
(0.25% DMSO).
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Synthesis of novobiocin-based urea analogs.
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Continued synthesis of novobiocin-based urea analogs.
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Table 1
IC50 values determined for compounds 1 and 2 against the MCF7 and A549 cancer cell lines as well as the 
normal human cell line, MRC5.
IC50 Values (μM)
Cell Line 1 2
MCF7 0.77 ± 0.01 0.17 ± 0.07
A549 0.24 ± 0.00 0.15 ± 0.02
MRC-5 3.6 4.3
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Table 2
IC50 values of compounds 3, 4 and 5 against the A549 lung cancer cell line.
Compound A549 Cell Line IC50 Values (μM)
3 0.06 ± 0.02
4 0.41 ± 0.13
5 0.28 ± 0.04
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